Richard J. Daly joined the Opiant Board of Directors in June 2018. He currently serves as President of CARsgen Therapeutics Corporation, a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. He also currently sits on the board of directors of Catalyst Pharmaceuticals.
Mr. Daly brings approximately 30 years of experience in the pharmaceutical industry. Before joining CARsgen, he served as Chief Operating Officer of BeyondSpring, Inc, a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies. Prior to Beyond Spring, Mr. Daly served as Chief Executive Officer, President and Chairman of Neuralstem, Inc. Before that, he served in AstraZeneca as the President of the U.S. Diabetes subsidiary (formerly BMS-AZ Diabetes Alliance). Earlier, Mr. Daly served as a Co-Founder of, and an investor in, Sagepath Partners, a company providing the pharmaceutical industry with outsourced commercial services. From 1991 to 2011, Mr. Daly served at Takeda and TAP Pharmaceuticals, a joint venture established between Takeda and Abbott Laboratories, holding several leadership positions, including the Executive Vice President at Takeda Pharmaceutical North America and the Senior Vice President of marketing at TAP Pharmaceuticals.
Mr. Daly holds an MBA from Kellogg School of Management at Northwestern University and a Bachelor of Science degree from University of Notre Dame.